The American Journal of Medicine
Volume 122, Issue 2, Supplement , Pages S33-S45 , February 2009

Osteonecrosis of the Jaw and the Role of Bisphosphonates: A Critical Review

  • Stuart L. Silverman, MD

      Affiliations

    • Cedars-Sinai Medical Center and David Geffen School of Medicine, University of California–Los Angeles, Los Angeles, California, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Stuart L. Silverman, MD, Cedars-Sinai/UCLA, 8641 Wilshire Blvd, Suite 301, Beverly Hills, California 90211
    • ,
  • Regina Landesberg, DMD, PhD

      Affiliations

    • Division of Oral and Maxillofacial Surgery, Columbia University, New York, New York, USA

References 

  1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1118
  2. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253-4234
  3. Ruggiero SL, Mehrotra B, Rosenberg T, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–534
  4. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567–1575
  5. American Association of Endodontists. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws [AAE Position Statement]. http://www.tupeloendo.com/pdfs/Bisphosphonate-Associated-Osteonecrosis.pdfAccessed July 10, 2008
  6. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137:1144–1150
  7. American Academy of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. http://www.aaoms.org/docs/position_papers/osteonecrosis.pdfAccessed December 11, 2006
  8. Khosla S, Burr D, Cauley J, et al. American Society for Bone and Mineral Research Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479–1491
  9. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Phys. 2006;35:801–803
  10. American College of Rheumatology. Bisphosphonate-associated osteonecrosis of the jaw [ACR Hotline]. Atlanta, GA: American College of Rheumatology; June 1, 2006. http://www.rheumatology.org/publications/hotline/0606onj.aspAccessed March 12, 2008
  11. Ruggiero SL, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006;2:7–14
  12. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397–2410
  13. de Papp AE, Kagan R, Buinewicz A, et al. Reference range for bone turnover markers in healthy premenopausal women: a comparison of oral contraceptive users and non-users. Presented at the 27th Annual Meeting of the ASBMR; 2005; Nashville, Tennessee. Abstract SU158.
  14. Hansen T, Kunkel M, Weber A, Kirkpatrick CJ. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35:155–160
  15. Hansen T, Kunkel M, Kirkpatrick CJ, Weber A. Actinomycosis in infected osteoradionecrosis: underestimated?. Hum Pathol. 2006;37:61–67
  16. Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med. 2004;117:440–441
  17. Cunha BA. Osteomyelitis in elderly patients. Clin Infect Dis. 2002;35:287–293
  18. Støre G, Eribe ERK, Olsen I. DNA-DNA hybridization demonstrates multiple bacteria in osteoradionecrosis. Int J Oral Maxillofac Surg. 2005;34:193–196
  19. Russo TA. Agents of actinomycosis. In:  Mandell GL,  Bennett JE,  Dolin R editor. Principles and Practice of Infectious Diseases. 4th ed.. New York: Churchill Livingstone; 1995;p. 2280–2288
  20. Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B. Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun. 1996;64:2371–2380
  21. Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–761
  22. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J. 2003;48:268
  23. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates [letter]. N Engl J Med. 2005;353:99
  24. Shane E, Goldring S, Christakos S, et al. Osteonecrosis of the jaw: more research needed [editorial]. J Bone Miner Res. 2006;21:1503–1505
  25. Black DM, Delmas PD, Eastell R HORIZON Pivotal Fracture Trial Group. Once-yearly zoledronic acid 5 mg for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822
  26. Grbic JT, Landesberg R, Lin S-Q Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial. J Am Dent Assoc. 2008;139:32–40
  27. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–836
  28. Murad O, Arora S, Farag A, Guber H. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Presented at ENDO 2006: The Endocrine Society's 88th Annual Meeting; June 24-27, 2006; Boston, Massachusetts. Abstract P2-500.
  29. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc. 2008;139:23–30
  30. Felsenberg D, Hoffmeister B, Amling M, et al. Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Arztebl. 2006;103:3078–3081
  31. Rizzoli R, Burlet N, Cahall D, et al. Impact of osteonecrosis of the jaw on osteoporosis management: executive summary of an ESCEO and Foundation for Research on Osteoporosis and Other Bone Diseases Working Group Meeting. Aging Health. 2007;6:731–734
  32. Mavrokokki A, Cheng A, Stein B, Goss AN. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415–423
  33. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone. 2007;41:318–320
  34. Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66:839–847
  35. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016–1021
  36. Twiss IM, de Water R, den Hartigh J, et al. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci. 1994;83:699–703
  37. Twiss IM, Pas O, Ramp-Koopmanschap W, et al. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J Bone Miner Res. 1999;14:784–791
  38. Wallace JL, Dicay M, McKnight W, et al. N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation. Aliment Pharmacol Ther. 1999;13:1675–1682
  39. Suri S, Mönkkönen J, Taskinen M, et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone. 2001;29:336–343
  40. Leyvraz S, Hess U, Flesch G, et al. Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst. 1992;84:788–792
  41. King LE, Vieth R. Extraction and measurement of pamidronate from bone samples using automated pre-column derivatization, high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Appl. 1996;678:325–330
  42. Hoggarth CR, Bennett R, Daley-Yates PT. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif Tissue Int. 1991;49:416–420
  43. Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res. 2007;22:1502–1509
  44. Stepan JJ, Burr DB, Pavo I, et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone. 2007;41:378–385
  45. Black D, Schwartz A, Ensrud K, et al. A 5-year randomized trial of the long-term efficacy and safety of alendronate: the FIT Long-term Extension (FLEX) [abstract]. J Bone Miner Res. 2004;19(suppl 1):S45
  46. Bone HG, Hosking D, Devogelaer J-P, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–1199
  47. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004;34:736–746
  48. Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997;100:1475–1480
  49. Recker R, Masarachia P, Santora A, et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin. 2005;21:185–194
  50. Recker R, Ensrud K, Diem S, et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women [abstract]. J Bone Miner Res. 2004;19(suppl 1):S45
  51. Borah B, Dufresne TE, Ritman EL, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone. 2006;39:345–352
  52. Eriksen EF, Melsen F, Sod E, et al. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002;31:620–625
  53. Devogelaer JP, Burckhardt P, Meunier P, et al. ZOL safety and efficacy over 5 years in post-menopausal osteoporosis. Osteoporosis Int. 2006;17(suppl 1):S14–S15Abstract OC40
  54. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin. 2004;20:1291–1300
  55. Nishii T, Sugano N, Miki H, et al. Does alendronate prevent collapse in osteonecrosis of the femoral head?. Clin Orthop Relat Res. 2006;443:273–279
  56. Lai KA, Shen WJ, Yang CY, et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis: a randomized clinical study. J Bone Joint Surg Am. 2005;87:2155–2159
  57. Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip: a prospective open-label study [published correction appears in Rheumatology (Oxford). 2005;44:569]. Rheumatology (Oxford). 2005;44:352–359
  58. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62:6538–6544
  59. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharm Exp Ther. 2002;302:1055–1061
  60. Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32:94–124

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)01193-5

doi: 10.1016/j.amjmed.2008.12.005

The American Journal of Medicine
Volume 122, Issue 2, Supplement , Pages S33-S45 , February 2009

Article Tools

* Image Usage & Resolution